Onco360’s Pharmacy Network the Choice for New Oncology Treatments

The second quarter of 2020 has seen Onco360’s pharmacy network be the choice by a number of pharmaceutical manufacturers to distribute new treatments in oncology. These include:

  • Eli Lilly for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
  • Seattle Genetics for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
  • AstraZeneca for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.

Onco360, a subsidiary of PharMerica, is one of the nation’s leading providers of Oncology Pharmacy services.  Onco360 is an Oncology Pharmacy whose clinical and dispensing model was developed specifically to meet the specialized needs of cancer patients, and the medical teams that help care for them.

PharMerica’s pharmacy teams serve long-term care, senior living, hospital, home infusion, behavioral, specialty and oncology pharmacy markets. For more than 30 years, Pharmerica, a leading institutional pharmacy, has provided  industry-leading technology and 24/7/365 medication dispensing.

Global investment firm KKR and BrightSpring Health Services (BrightSpring), one of the largest home and community-based health services providers, announced in 2019 that KKR closed on its acquisition of BrightSpring. As part of this transaction, BrightSpring merged with PharMerica to now become a leading provider of both home and community-based health and pharmacy services for high-need and medically complex populations.


Takeaway: Onco360’s patient-centric approach to cancer care has resulted in its market-leading position in oncology pharmacy